Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2015 May;42(5):439-445.
doi: 10.1016/j.nucmedbio.2014.12.011. Epub 2014 Dec 23.

Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals

Affiliations

Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals

Marek Pruszyński et al. Nucl Med Biol. 2015 May.

Abstract

Introduction: The heavy halogen (211)At is of great interest for targeted radiotherapy because it decays by the emission of short-range, high-energy α-particles. However, many astatine compounds that have been synthesized are unstable in vivo, providing motivation for seeking other (211)At labeling strategies. One relatively unexplored approach is to utilize prosthetic groups based on astatinated rhodium (III) complex stabilized with a tetrathioether macrocyclic ligand - Rh[16aneS(4)-diol](211)At. The purpose of the current study was to evaluate the in vitro and in vivo stability of this complex in comparison to its iodine analog - Rh[16aneS(4)-diol](131)I.

Methods: Rh[16aneS(4)-diol](211)At and Rh[16aneS(4)-diol](131)I complexes were synthesized and purified by HPLC. The stability of both complexes was evaluated in vitro by incubation in phosphate-buffered saline (PBS) and human serum at different temperatures. The in vivo behavior of the two radiohalogenated complexes was assessed by a paired-label biodistribution study in normal Balb/c mice.

Results: Both complexes were synthesized in high yield and purity. Almost no degradation was observed for Rh[16aneS(4)-diol](131)I in PBS over a 72 h incubation. The astatinated analog exhibited good stability in PBS over 14 h. A slow decline in the percentage of intact complex was observed for both tracers in human serum. In the biodistribution study, retention of (211)At in most tissues was higher than that of (131)I at all time points, especially in spleen and lungs. Renal clearance of Rh[16aneS(4)-diol](211)At and Rh[16aneS(4)-diol](131)I predominated, with 84.1 ± 2.3% and 94.6 ± 0.9% of injected dose excreted via the urine at 4 h.

Conclusions: The Rh[16aneS(4)-diol](211)At complex might be useful for constructing prosthetic groups for the astatination of biomolecules and further studies are planned to evaluate this possibility.

Keywords: Astatine-211; Macrocyclic thioether; Prosthetic groups; Radioiodination; Rhodium complexes.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
Stability of Rh[16aneS4-diol]131I complex over time at different temperatures in: (A) phosphate buffered-saline (PBS); (B) human serum.
Fig. 2
Fig. 2
Stability of Rh[16aneS4-diol]211At complex over time at different temperatures in: (A) phosphate buffered-saline (PBS); (B) human serum.
Fig. 3
Fig. 3
Uptake of 211At and 131I activity in mouse thyroid after administration of Rh[16aneS4-diol]211At (filled bars) and Rh[16aneS4-diol]131I (open bars) in normal Balb/c mice.

Similar articles

Cited by

References

    1. Ersahin D, Doddamane I, Cheng D. Targeted radionuclide therapy. Cancers. 2011;3:3838–3855. - PMC - PubMed
    1. Oyen WJG, Bodei L, Giammarile F, Maecke HR, Tennvall J, Luster M, et al. Targeted therapy in nuclear medicine - current status and future prospects. Ann Oncol. 2007;18:1782–1792. - PubMed
    1. Hall EJ, Giaccia AJ. Radiobiology for the Radiologist. 6th ed. Philadelphia: Lippincott Williams & Wilkins; 2006.
    1. Wicha MS. Cancer stem cells and metastasis: lethal seeds. Clin Cancer Res. 2006;12:5606–5607. - PubMed
    1. Al-Ejeh F, Smart CE, Morrison BJ, Chenevix-Trench G, Lopez JA, Lakhani SR, et al. Breast cancer stem cells: treatment resistance and therapeutic opportunities. Carcinogenesis. 2011;32:650–658. - PubMed

Publication types

LinkOut - more resources